CL2024002832A1 - Terapias de combinación - Google Patents

Terapias de combinación

Info

Publication number
CL2024002832A1
CL2024002832A1 CL2024002832A CL2024002832A CL2024002832A1 CL 2024002832 A1 CL2024002832 A1 CL 2024002832A1 CL 2024002832 A CL2024002832 A CL 2024002832A CL 2024002832 A CL2024002832 A CL 2024002832A CL 2024002832 A1 CL2024002832 A1 CL 2024002832A1
Authority
CL
Chile
Prior art keywords
effective amount
therapeutically effective
combination therapies
combinations
formula
Prior art date
Application number
CL2024002832A
Other languages
English (en)
Inventor
Daskalakis Nikki
Diane Guttke Christina
Chul Kwon Min
Angela Ferrante Lucille
Elizabeth Packman Kathryn
Christine Pietsch Eva
Philippar Ulrike
Ann J Verhulst Tinne
Bhogal Balpreet
Sun Yu
Cai Wei
Alexis Georges Querolle Olivier
Wilhelmus J Thuring Johannes
Liu Yingtao
Liu Lianzhu
Xu Yanping
Fu Liqiang
Fang Lichao
Deng Xiangjun
Tee Fuay Ng Alicia
Freddy J Darville Nicolas
Pande Vineet
Li Ming
Dai Xuedong
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2024002832A1 publication Critical patent/CL2024002832A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen combinaciones que comprenden una cantidad terapéuticamente efectiva de un inhibidor de menina-MLL de la Fórmula (I) o una sal farmacéuticamente aceptable o un solvato de este; y una cantidad coterapéuticamente efectiva de un inhibidor de BCL-2; y opcionalmente, una cantidad terapéuticamente efectiva de al menos un otro agente antineoplásico. También se describen métodos para tratar a un sujeto que ha sido diagnosticado con un trastorno hematopoyético usando tales combinaciones. Los compuestos se representan mediante la Fórmula (I), en donde R1a, R1b, R2, R3, R4, U, Y1, X1, X2, n1, n2, n3 y n4 se definen en la presente descripción.
CL2024002832A 2021-05-11 2024-09-23 Terapias de combinación CL2024002832A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021093036 2021-05-11
CN2021100523 2021-06-17
CN2022086004 2022-04-11

Publications (1)

Publication Number Publication Date
CL2024002832A1 true CL2024002832A1 (es) 2025-02-14

Family

ID=81753154

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2023003239A CL2023003239A1 (es) 2021-05-11 2023-10-31 Terapias de combinación
CL2024002832A CL2024002832A1 (es) 2021-05-11 2024-09-23 Terapias de combinación

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2023003239A CL2023003239A1 (es) 2021-05-11 2023-10-31 Terapias de combinación

Country Status (16)

Country Link
EP (1) EP4337216A1 (es)
JP (1) JP2024518497A (es)
KR (1) KR20240006631A (es)
CN (2) CN117460513A (es)
AU (1) AU2022274071A1 (es)
CA (1) CA3215313A1 (es)
CL (2) CL2023003239A1 (es)
CO (1) CO2023014322A2 (es)
DO (1) DOP2023000246A (es)
IL (1) IL308335A (es)
MX (1) MX2023013410A (es)
PE (1) PE20240593A1 (es)
PH (1) PH12023552974A1 (es)
TW (1) TW202308643A (es)
UY (1) UY39761A (es)
WO (1) WO2022237720A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
EP4626426A1 (en) * 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
WO2024114666A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
EP4698182A1 (en) * 2023-04-17 2026-02-25 Janssen Pharmaceutica NV Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder
WO2025082444A2 (en) * 2023-10-20 2025-04-24 Janssen Pharmaceutica Nv (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000080A1 (en) 2014-12-18 2018-07-04 Takeda Pharmaceuticals Co Solid state forms of fused heteroaromatic pyrrolidinones
AU2016378579A1 (en) * 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
WO2017214367A1 (en) * 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物

Also Published As

Publication number Publication date
AU2022274071A1 (en) 2024-01-04
MX2023013410A (es) 2023-12-06
JP2024518497A (ja) 2024-05-01
CO2023014322A2 (es) 2023-11-20
DOP2023000246A (es) 2024-04-30
IL308335A (en) 2024-01-01
CA3215313A1 (en) 2022-11-17
PH12023552974A1 (en) 2024-03-11
CL2023003239A1 (es) 2024-06-07
PE20240593A1 (es) 2024-03-21
TW202308643A (zh) 2023-03-01
CN118845787A (zh) 2024-10-29
UY39761A (es) 2022-11-30
CN117460513A (zh) 2024-01-26
EP4337216A1 (en) 2024-03-20
WO2022237720A1 (en) 2022-11-17
KR20240006631A (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
CL2024002832A1 (es) Terapias de combinación
CL2024002893A1 (es) Terapias de combinación
CO2022017072A2 (es) Imidazopiridazinas como moduladores de il-17
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
BR112022010377A2 (pt) Novos tiromiméticos
CO2021008816A2 (es) Moduladores de trex1
MX2024009926A (es) Composiciones y metodos para tratar trastornos del snc.
CR9828A (es) Nueva forma de dosificacion farmaceutica de liberacion modificada para un inhibidor de la enzima ciclooxigenasa
CL2024001620A1 (es) Inhibidores del sarcómero cardíaco
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
CO2022008719A2 (es) Compuestos para modular la actividad de fxr y usos de los mismos
CO2021017202A2 (es) Compuestos tricíclicos
MX2023010506A (es) Composiciones que comprenden profarmacos de escision enzimatica y nafamostat de liberacion controlada y metodos de uso de estos.
CL2024001481A1 (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
MX2020011367A (es) Compuesto oxo-sustituido.
CL2023003253A1 (es) Moduladores de trex1
CO2025016753A2 (es) Inhibidores de gsk3α y métodos de uso de estos
CL2023003168A1 (es) Moduladores de trex1
AR115921A1 (es) Ácido isolitocólico o ácido isoalolitocólico y derivados deuterados de los mismos para prevenir y tratar enfermedades asociadas a clostridium difficile
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
CL2021002144A1 (es) Compuesto heterociclo pentacíclico.
AR107310A1 (es) Inhibidores de tetrahidrocarbazol de receptores sirt1
MX2022002000A (es) Derivados de pirazol y uso de los mismos.
CO2022002670A2 (es) Método para bloquear o mejorar el síndrome de liberación de citocinas
MX2023001742A (es) Agente terapeutico para la enfermedad de higado graso.